The Immunological Monitoring Core provides immunologic and biological assay support for ongoing research projects and clinical trials at the Cancer Center and the biomedical community at the University of Michigan. Services are provided in three different areas. First, simultaneous detection of numerous cytokines, chemokines, hormones and other released proteins and the related technical support are provided on a continued basis for investigators. These assays are performed with the Luminex System, and via ELISA using a robotics pipetting station. Second, TAA-specific T cell response assays will be provided to investigators. These assays Include TAA-specific cytokine ELISA spot by using the AID ELISPOT Plate Reader, and TAA-specific T cell proliferation and CTL activities. Third, the Core provides time standard technical services to support clinical research protocols in the immunobiology area for Investigators who do not have standard wet laboratory space. This facility will provide the opportunity to have tissues processed and analyzed for general immune parameters, standard lymphocyte and tumor proliferation assays, as well as quantification of cytokines. These Immune assays may not nomially be available In the non-immunology laboratory, The Core also provides expert advice that helps investigators select appropriate immune assays using appropriate reagents and apply them to best advantage.
The services provided by the immune Monitoring Core support research by investigators involved in immunological approaches to the treatment of cancer. The overall goal of this core is to extend or improve the quality of life of cancer patients through immune mechanisms.
|Skolarus, Ted A; Metreger, Tabitha; Hwang, Soohyun et al. (2017) Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials 18:181|
|Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668|
|Pinskey, Justine M; Franks, Nicole E; McMellen, Alexandra N et al. (2017) Neuropilin-1 promotes Hedgehog signaling through a novel cytoplasmic motif. J Biol Chem 292:15192-15204|
|Maj, Tomasz; Wang, Wei; Crespo, Joel et al. (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332-1341|
|Zhang, Jie; Feng, Shumei; Su, Wenmei et al. (2017) Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep 7:42819|
|Mann, J E; Hoesli, R; Michmerhuizen, N L et al. (2017) Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer 8:332-344|
|Birkeland, Andrew C; Foltin, Susan K; Michmerhuizen, Nicole L et al. (2017) Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncol 68:5-8|
|Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852|
|Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188|
|Chen, Yan; Zhou, Quan; Li, Xue et al. (2017) Ultrasmall Paramagnetic Iron Oxide Nanoprobe Targeting Epidermal Growth Factor Receptor for In Vivo Magnetic Resonance Imaging of Hepatocellular Carcinoma. Bioconjug Chem 28:2794-2803|
Showing the most recent 10 out of 1355 publications